NCT00006364View on ClinicalTrials.gov

Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 1999

Primary Completion Date

September 30, 2005

Conditions

Childhood Chronic Myelogenous LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Phase Chronic Myelogenous LeukemiaRelapsing Chronic Myelogenous Leukemia

Interventions

DRUG

omacetaxine mepesuccinate

Given IV or SC

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00006364 - Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia | Biotech Hunter | Biotech Hunter